Zum Hauptinhalt springen
xMedica

NCT07784725ClinicalTrials.gov

A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus

A Phase III Randomised, Double-Blind, Placebo-Controlled Multicentre Trial to Evaluate the Efficacy and Safety of AZD6234 in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity Without Type 2 Diabetes Mellitus (SELENE 1)

RekrutiertNimmt laut Registereintrag derzeit Teilnehmende auf.
Diese Studie kontaktieren

Kurz gefasst

The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment

Phase 32.500 Teilnehmende gesucht220 Studienzentren16 Länder

Kategorien

In 1 Register registriert

Eine Studie kann in mehreren Registern registriert sein. Wir zeigen sie einmal und verlinken jeden Eintrag, den wir haben.

Die Studieninformationen werden so angezeigt, wie sie vom Register veröffentlicht wurden, in ihrer Originalsprache.

Interesse an dieser Studie?

Anmelden oder ein Konto erstellen um Ihr Interesse zu bekunden und diese Studie zu verfolgen.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Not stated: Registered after enrolment began (about 6 days after the recorded start)First posted 2026-08-25; recorded start 2026-08-19
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Present: Participants are randomly assignedAllocation is recorded as randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Present: Uses blinding (masking)A masking level is recorded in the record
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 1038 other studies in this databaseCounted from the lead sponsor named in the record (AstraZeneca)
  • Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourSTRONG

A strong methodological design for a phase 3 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding20/20

    Quadruple-blind

  • Control arm13/15

    Placebo / sham control arm

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre8/8

    Multi-centre: 212 sites

  • Data monitoring committee0/7

    No data monitoring committee stated

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleLARGE

A large study, international in scope: 2,500 participants (target), run at 220 sites, across 16 countries.

How this score is built
  • Enrolment34/40

    2,500 participants (target)

  • Site count25/25

    212 sites

  • Country count15/15

    16 countries

  • Planned duration8/10

    Planned over about 34 months

  • Sponsor scale10/10

    AstraZeneca has led 1,017 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Zusammenfassung

The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment

This is a Phase III, global, randomised, parallel-group, double-blind, multicentre study to assess the efficacy and safety of AZD6234 compared with placebo, administered SC once weekly in adults with obesity or overweight with at least one weight-related comorbidity without T2DM. Eligible participants will be randomized to either receive AZD6234 or matching placebo respectively.

Erkrankungen

  • Obesity or Overweight

Eignung

Eignung
GeschlechtAlle
Alter18 Years – Kein Höchstalter
Gesunde FreiwilligeNein

Eignung im Wortlaut des Registers

Inclusion Criteria: * Males \& females (inclusive of all gender identities) age ≥18 years * BMI ≥30 kg/m2 OR BMI ≥27 kg/m2 with at least one of the following weight related comorbidities (treated or untreated): hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, heart failure, chronic kidney disease, metabolic dysfunction-associated steatotic liver disease, osteoarthritis of the knee, or stress urinary incontinence * Stable body weight (≤5% body weight change) for at least 3 months prior to Randomisation * History of at least one self-reported unsuccessful attempt to lose body weight in their lifetime Exclusion Criteria: * Obesity primarily caused by other endocrine disorders * History of Type 1 or Type 2 Diabetes Mellitus, HbA1c ≥6.5% (48 mmol/mol), and/or treatment with glucose-lowering agent(s) within 3 months prior to Screening * Significant hepatobiliary disease and/or any of the following results at Screening: * ALT ≥ 3.0 × ULN * AST ≥ 3.0 × ULN * TBL \> 1.5 × ULN (except for cases of known Gilbert's Syndrome) * Has received treatment with a GLP-1 receptor agonist or GLP-1 containing medication for any indication within 3 months before Randomisation.

Eignung in einfachen Aussagen

Die Kriterien dieses Eintrags wurden noch nicht in einzelne Aussagen aufgeschlüsselt. Der Registertext oben ist vollständig und ist die maßgebliche Fassung.

Studiendesign

Studiendesign
StudientypInterventionell
PhasePhase 3
ZuteilungRandomisiert
InterventionsmodellPARALLEL
Primäres ZielTREATMENT
VerblindungQUADRUPLE (4)
Teilnahme2.500 Teilnehmende gesucht

Sponsor und Mitwirkende

  • AstraZeneca Sponsor

Studienarme und Interventionen

  • AZD6234 Dose 1EXPERIMENTAL

    AZD6234 Dose 1

  • AZD6234 Dose 2EXPERIMENTAL

    AZD6234 Dose 2

  • PlaceboPLACEBO_COMPARATOR

    Matching placebo

Interventionen

  • Arzneimittel Lenbelintide

    IMP injected subcutaneously, once a week. Unit dose strength as per CSP.

  • Arzneimittel Placebo

    Placebo matching IMP dose injected subcutaneously, once a week.

Endpunkte

  1. Primärer Endpunkt

    Percent change in body weight from baseline at 68 weeks of treatment

    To evaluate the effect of AZD6234 as compared to placebo in percent body weight change

    Zeitrahmen 68 weeks

  2. Sekundärer Endpunkt

    Absolute change in weight (kg) from baseline at 68 weeks of treatment

    To evaluate the effect of AZD6234 as compared to placebo on absolute change in weight

    Zeitrahmen 68 weeks

  3. Sekundärer Endpunkt

    Achievement of at least 5 % body weight loss from baseline at 68 weeks of treatment

    To evaluate the effect of AZD6234 as compared to placebo in body weight loss of at least 5%

    Zeitrahmen 68 weeks

  4. Sekundärer Endpunkt

    Achievement of at least 10% body weight loss from baseline at 68 weeks of treatment

    To evaluate the effect of AZD6234 as compared to placebo in body weight loss of at least 10%

    Zeitrahmen 68 weeks

  5. Sekundärer Endpunkt

    Change in waist circumference (cm) from baseline at 68 weeks of treatment

    To evaluate the effect of AZD6234 as compared to placebo on waist circumference change

    Zeitrahmen 68 weeks

  6. Sekundärer Endpunkt

    Percent change in triglycerides from baseline at 68 weeks of treatment

    To evaluate the effect of AZD6234 as compared to placebo on triglycerides percent change

    Zeitrahmen 68 weeks

  7. Sekundärer Endpunkt

    Change in systolic blood pressure (mmHg) from baseline at 68 weeks of treatment

    To evaluate the effect of AZD6234 as compared to placebo on systolic blood pressure change

    Zeitrahmen 68 weeks

  8. Sekundärer Endpunkt

    Percent change in fat mass from baseline at 68 weeks of treatment measured by DXA in the DXA Sub-Study subset

    Body Composition Sub-study: To evaluate the effect of AZD6234 as compared to placebo on body composition change in the DXA subset of participants

    Zeitrahmen 68 weeks

Daten

Daten
Startdatum19. August 2026 (tatsächlich)
Primärer Abschluss11. August 2028 (geschätzt)
Abschluss21. Mai 2029 (geschätzt)
Erstveröffentlichung25. August 2026 (tatsächlich)
Zuletzt aktualisiert30. Oktober 2026
Ergebnisse veröffentlichtIm Registereintrag nicht angegeben
Status zuletzt bestätigtOktober 2026

Tatsächlich bedeutet, dass das Ereignis eingetreten ist. Geschätzt bedeutet, dass der Sponsor es erwartet. Die beiden bedeuten Unterschiedliches.

Standorte

76 Studienzentren rekrutieren

Argentina

Argentina
EinrichtungStadtBundesland oder RegionStatus
Research SiteBuenos AiresRekrutiert
Research SiteBuenos AiresRekrutiert
Research SiteCiudad de Buenos AiresRekrutiert
Research SiteMendozaRekrutiert
Research SiteRamos MejíaRekrutierung noch nicht begonnen
Research SiteRosarioRekrutiert
Research SiteSan NicolásRekrutierung noch nicht begonnen

Australia

Australia
EinrichtungStadtBundesland oder RegionStatus
Research SiteBotanyRekrutiert
Research SiteCamberwellRekrutiert
Research SiteCharlestownRekrutiert
Research SiteSt AlbansRekrutiert
Research SiteSt LeonardsRekrutiert
Research SiteWaitaraRekrutiert

Brazil

Brazil
EinrichtungStadtBundesland oder RegionStatus
Research SiteBelo HorizonteRekrutierung noch nicht begonnen
Research SiteBrasíliaRekrutierung noch nicht begonnen
Research SiteCampinasRekrutierung noch nicht begonnen
Research SiteCampinasRekrutierung noch nicht begonnen
Research SiteCuritibaZurückgezogen
Research SiteCuritibaRekrutierung noch nicht begonnen
Research SiteCuritibaRekrutierung noch nicht begonnen
Research SiteNatalRekrutierung noch nicht begonnen
Research SitePorto AlegreRekrutierung noch nicht begonnen
Research SiteRio de JaneiroRekrutierung noch nicht begonnen
Research SiteSão José dos CamposRekrutierung noch nicht begonnen
Research SiteSão PauloRekrutierung noch nicht begonnen

Bulgaria

Bulgaria
EinrichtungStadtBundesland oder RegionStatus
Research SiteMontanaRekrutierung noch nicht begonnen
Research SitePlevenRekrutierung noch nicht begonnen
Research SitePlovdivRekrutiert
Research SiteSofiaRekrutiert
Research SiteSofiaRekrutiert
Research SiteSofiaRekrutiert
Research SiteVarnaRekrutierung noch nicht begonnen
Research SiteYambolRekrutiert

Canada

Canada
EinrichtungStadtBundesland oder RegionStatus
Research SiteBramptonOntarioRekrutiert
Research SiteCalgaryAlbertaRekrutiert
Research SiteGuelphOntarioRekrutiert
Research SiteHamiltonOntarioRekrutiert
Research SiteMississaugaOntarioRekrutiert
Research SiteMonctonNew BrunswickRekrutiert
Research SiteMontrealQuebecRekrutiert
Research SiteNew WestminsterBritish ColumbiaRekrutiert
Research SiteNorth YorkOntarioRekrutiert
Research SiteQuébecQuebecRekrutiert
Research SiteQuébecQuebecRekrutiert
Research SiteSaint-Charles-BorroméeQuebecRekrutiert
Research SiteScarborough VillageOntarioRekrutiert
Research SiteSherbrookeQuebecRekrutiert
Research SiteStoney CreekOntarioRekrutiert
Research SiteStouffvilleOntarioRekrutiert
Research SiteSurreyBritish ColumbiaZurückgezogen

170 weitere Studienzentren sind im Registereintrag aufgeführt.

Studiendokumente

In diesem Registereintrag sind keine Dokumente verlinkt.

Änderungen im Zeitverlauf

  1. 30. Oktober 2026

    Studienzentrum hinzugefügt

    8 sites added (220 total)

    212220